Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Temperature Excursion Notification and Documentation – V 2.0

Posted on By

BA-BE Studies: SOP for Temperature Excursion Notification and Documentation – V 2.0

Standard Operating Procedure for Temperature Excursion Notification and Documentation in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/127/2025
Supersedes SOP/BA-BE/127/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define a clear procedure for the identification, notification, impact assessment, and documentation of temperature excursions involving investigational products and biological samples in BA/BE studies.

2. Scope

This SOP is applicable to all clinical, logistics, and bioanalytical staff responsible for monitoring, managing, and documenting storage and transport temperatures of temperature-sensitive materials and samples in BA/BE trials.

3.

Responsibilities
  • Bioanalytical or Clinical Staff: Monitors storage temperatures and records excursions.
  • Facility Maintenance Team: Investigates equipment malfunction and restores acceptable storage conditions.
  • Principal Investigator/Sponsor Representative: Evaluates impact on sample integrity.
  • Quality Assurance: Verifies excursion handling and performs trending analysis.

4. Accountability

The Head of Clinical Research or Bioanalytical Operations is accountable for ensuring timely identification, reporting, and resolution of temperature excursions to protect data integrity and subject safety.

5. Procedure

5.1 Temperature Monitoring Setup

  1. All sample freezers, refrigerators, and transport boxes must have:
    • Calibrated digital thermometers
    • Continuous data loggers
    • Visual/audible temperature alarms
  2. Record daily temperature logs and maintain deviation thresholds:
    • -70°C freezers: Acceptable range ±10°C
    • -20°C freezers: Acceptable range ±5°C
    • 2–8°C refrigerators: Acceptable range ±2°C

5.2 Identification of Temperature Excursion

  1. Excursion is defined as any temperature reading outside of validated storage conditions.
  2. When identified:
    • Immediately note deviation in Annexure-1: Temperature Excursion Log
    • Activate internal alarm response procedure

5.3 Notification and Impact Assessment

  1. Notify:
    • Bioanalytical/clinical team lead
    • QA representative
    • Sponsor representative (if required)
  2. Evaluate:
    • Duration and range of excursion
    • Type and quantity of samples/materials impacted
    • Stability data of affected materials (refer CoA)
  3. Document assessment in Annexure-2: Excursion Impact Assessment Form

5.4 Corrective and Preventive Actions (CAPA)

  1. Determine root cause (e.g., power failure, equipment malfunction, human error).
  2. Initiate CAPA using Annexure-3: Excursion CAPA Form.
  3. Preventive actions may include:
    • Staff retraining
    • Alarm calibration
    • Alternative backup freezer allocation

5.5 Documentation and Archival

  1. Maintain all logs and assessment forms in the Study Master File (SMF) and QA repository.
  2. QA to perform monthly trend review and compile Annexure-4: Excursion Trend Report.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • CAPA: Corrective and Preventive Action
  • QA: Quality Assurance
  • CoA: Certificate of Analysis
  • SMF: Study Master File

7. Documents

  1. Temperature Excursion Log – Annexure-1
  2. Excursion Impact Assessment Form – Annexure-2
  3. Excursion CAPA Form – Annexure-3
  4. Excursion Trend Report – Annexure-4

8. References

  • ICH E6(R2) – Good Clinical Practice
  • WHO Technical Report Series on Stability of Biological Samples
  • 21 CFR Part 58 – GLP Guidelines

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Temperature Excursion Log

Date Time Location Recorded Temp Limit Action Taken
16/04/2025 03:15 AM FZ-70A -56.4°C -60 to -80°C Backup freezer used

Annexure-2: Excursion Impact Assessment Form

Date Material Affected Exposure Duration Assessment Comments
16/04/2025 Plasma Samples 35 min No impact (stability data supports) Reviewed by QA

Annexure-3: Excursion CAPA Form

Deviation Root Cause Corrective Action Preventive Action Closed By
High Temp in FZ-70A DG switch delay Manual switch initiated Alarm escalation protocol revised QA Manager

Annexure-4: Excursion Trend Report

Month Total Excursions Major Minor Trend
March 2025 3 1 2 Acceptable

Revision History:

Revision Date Revision No. Details Reason Approved By
12/01/2022 1.0 Initial Release Regulatory Compliance QA Head
17/04/2025 2.0 Added trend analysis and formalized impact assessment workflow Audit Recommendation QA Head
See also  BA-BE Studies: SOP for Document Control in Clinical Phase - V 2.0
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Biosimilars: SOP for Review and Approval of CLD Protocols – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version